Aimee S Payne

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 115:888-99. 2005
  2. ncbi Two novel TP63 mutations associated with the ankyloblepharon, ectodermal defects, and cleft lip and palate syndrome: a skin fragility phenotype
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, 220 Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104, USA
    Arch Dermatol 141:1567-73. 2005
  3. ncbi Dermatologic toxicity of chemotherapeutic agents
    Aimee S Payne
    Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Oncol 33:86-97. 2006
  4. pmc Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy
    John R Stanley
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Vet Dermatol 20:327-30. 2009
  5. pmc Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus
    Jun Yamagami
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 183:5615-21. 2009
  6. ncbi Targeting pemphigus autoantibodies through their heavy-chain variable region genes
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Invest Dermatol 127:1681-91. 2007
  7. pmc MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris
    Xuming Mao
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 134:68-76. 2014
  8. pmc Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity
    Jun Yamagami
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 120:4111-7. 2010
  9. ncbi Plakophilins, desmogleins, and pemphigus: the tail wagging the dog
    Christoph T Ellebrecht
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 134:874-6. 2014
  10. pmc Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis
    Misha Rosenbach
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
    JAMA Dermatol 149:550-6. 2013

Research Grants

Collaborators

Detail Information

Publications24

  1. pmc Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 115:888-99. 2005
    ..Detailed characterization of these pemphigus mAbs should lead to a better understanding of the immunopathogenesis of disease and to more specifically targeted therapeutic approaches...
  2. ncbi Two novel TP63 mutations associated with the ankyloblepharon, ectodermal defects, and cleft lip and palate syndrome: a skin fragility phenotype
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, 220 Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104, USA
    Arch Dermatol 141:1567-73. 2005
    ..Recent structure-function studies have identified complexities in the genotype-phenotype correlation of the p63 syndromes...
  3. ncbi Dermatologic toxicity of chemotherapeutic agents
    Aimee S Payne
    Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Oncol 33:86-97. 2006
    ..This review will focus on the cutaneous side effects of the newer classes of chemotherapy drugs, including targeted monoclonal antibody therapy and small molecule inhibitors...
  4. pmc Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy
    John R Stanley
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Vet Dermatol 20:327-30. 2009
    ..In summary, the antibody response is restricted and, therefore, it may be feasible to target the specific pathogenic antibodies for therapy...
  5. pmc Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus
    Jun Yamagami
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 183:5615-21. 2009
    ..However, presentation of peptides from Dsg1 by preDsg1-specific B cells may be one step in developing autoimmunity in PF...
  6. ncbi Targeting pemphigus autoantibodies through their heavy-chain variable region genes
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Invest Dermatol 127:1681-91. 2007
    ..Together, these data suggest novel V(H) gene-targeted approaches toward PV treatment...
  7. pmc MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris
    Xuming Mao
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 134:68-76. 2014
    ..Collectively, these data suggest that MK2 is a key downstream effector of p38 that can modulate PV autoantibody pathogenicity. MK2 inhibition may be a valuable adjunctive therapy for control of pemphigus blistering. ..
  8. pmc Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity
    Jun Yamagami
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 120:4111-7. 2010
    ..These studies indicate that H-CDR3 is critical for pathogenicity of a human autoantibody, that a small region (even 1 amino acid) can mediate pathogenicity, and that pathogenicity can be uncoupled from binding in these antibodies...
  9. ncbi Plakophilins, desmogleins, and pemphigus: the tail wagging the dog
    Christoph T Ellebrecht
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 134:874-6. 2014
    ..This study beautifully demonstrates that desmosomal adhesion can be modulated by the molecular interactions of the desmoglein tail and suggests that these novel regulatory pathways may possibly be exploited in treating human disease. ..
  10. pmc Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis
    Misha Rosenbach
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
    JAMA Dermatol 149:550-6. 2013
    ....
  11. pmc Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies
    Xuming Mao
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Invest Dermatol 129:908-18. 2009
    ..Monovalent human PV anti-Dsg mAbs reproduce the effects of polyclonal PV IgG on Dsg3 and will facilitate future studies to further dissect the cellular mechanisms for the loss of cell adhesion in pemphigus...
  12. pmc p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris
    Xuming Mao
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 286:1283-91. 2011
    ..Treatments aimed at increasing keratinocyte adhesion could be used in conjunction with immunosuppressive agents, potentially leading to safer and more effective combination therapy regimens...
  13. pmc Autoimmunity to desmocollin 3 in pemphigus vulgaris
    Xuming Mao
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA
    Am J Pathol 177:2724-30. 2010
    ....
  14. pmc Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF)
    Andrea Baratta
    Department of Dermatology, St John s Episcopal Hospital, Far Rockaway, New York, USA
    Pediatr Dermatol 30:240-4. 2013
    ..In summary, combination therapy with prednisone and MMF for pediatric PV appears to be a safe and effective approach that is associated with durable remission...
  15. pmc The autoimmune regulator (AIRE), which is defective in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients, is expressed in human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin
    Vipul Kumar
    Division of Immunology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Am J Pathol 178:983-8. 2011
    ..The cytoplasmic association of AIRE with the intermediate filament network in human epidermal and follicular keratinocytes may provide a new path to understanding the ectodermal abnormalities associated with the APECED syndrome...
  16. ncbi Desmosomes and disease: pemphigus and bullous impetigo
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, 415 Curie Boulevard, 211 Clinical Research Building, Pennsylvania, 19104 USA
    Curr Opin Cell Biol 16:536-43. 2004
    ..These studies offer new insight into the potential mechanisms of acantholysis in pemphigus and staphylococcal-associated blistering disease, with implications for the role of desmogleins in desmosomal structure and function...
  17. ncbi Seeking approval: present and future therapies for pemphigus vulgaris
    Xuming Mao
    University of Pennsylvania, Department of Dermatology, 217A Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104, USA
    Curr Opin Investig Drugs 9:497-504. 2008
    ..This review focuses on pemphigus therapies that are currently in preclinical or clinical trials, as well as potential novel therapies based on recent advances in the understanding of the pathophysiology of this disease...
  18. ncbi Beyond steric hindrance: the role of adhesion signaling pathways in the pathogenesis of pemphigus
    Preety Sharma
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
    J Dermatol Sci 48:1-14. 2007
    ..In this review, we will summarize the evidence supporting a role for steric hindrance and signaling mechanisms in the pathogenesis of pemphigus acantholysis and discuss potential analogues in the classical cadherin literature...
  19. ncbi Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients
    Michael Jeffrey Cho
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Commun 5:4167. 2014
    ..Common VH gene usage indicates common humoral immune responses, even among unrelated patients. ..
  20. ncbi Cloning and genetic characterization of human pemphigus autoantibodies
    Aimee S Payne
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 55:e2. 2006
  21. pmc Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients
    Luisa Lunardon
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Dermatol 148:1031-6. 2012
    ..The end point for efficacy was complete remission of disease taking no or minimal therapy...
  22. pmc Cleavage isn't everything: potential novel mechanisms of exfoliative toxin-mediated blistering
    Takeru Funakoshi
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA
    Am J Pathol 177:2682-4. 2010
    ..This Commentary describes breakthroughs in understanding the interactions between desmoglein 1 and plakogloben in staphylococcal-mediated blistering skin diseases...
  23. pmc Reliability and convergent validity of two outcome instruments for pemphigus
    Misha Rosenbach
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19119, USA
    J Invest Dermatol 129:2404-10. 2009
    ..Subset analysis suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variability in cutaneous disease than the ABSIS...
  24. pmc Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
    Dedee F Murrell
    Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
    J Am Acad Dermatol 58:1043-6. 2008
    ..These should assist in development of consistent reporting of outcomes in future studies...

Research Grants1

  1. Role of autoantibody isotype in pemphigus pathogenesis
    Aimee S Payne; Fiscal Year: 2010
    ....